5 Most Promising Psychedelic Stocks According To Analysts

Page 5 of 5

1. Mydecine Innovations Group Inc. (OTC:MYCOF)

Number of Hedge Fund Holders: N/A

Estimated 1-year Target Price: $140.00

Mydecine Innovations Group Inc. (OTC:MYCOF) was incorporated in 2013 and is headquartered in Vancouver, Canada. It is a biotech and life sciences company that engages in the development and commercialization of drugs for treating mental health problems. The company also provides psychedelic integration services, including psychedelic aftercare and wellness services. On December 12, Mydecine Innovations Group Inc. (OTC:MYCOF) completed the sale of its wholly-owned subsidiary, Mindleap Health, to PanGenomic Health. As per the announcement, PanGenomic acquired all the outstanding shares of Mindleap Health by issuing units of PanGenomic at a price of C$0.20 per unit. The purchase price for all of Mindleap Health’s shares was C$3.6 million.

Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily enewsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below. You can also check out 10 Small Cap SaaS Stocks Hedge Funds are Piling Into and 13 Most Profitable Food Stocks

Page 5 of 5